Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer. Serum levels of macrophage inhibitory cytokine-1 (MIC1) and matrix ...

Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. This is an ASCO Meeting Abstract from the 2015 Gastrointestinal ...

Two distinct subtypes discovered, each with dramatically different risks of recurrence Patients with more aggressive subtype can be monitored vigilantly for recurrence and possible treatment, while ...

SEATTLE -- Surgery for pancreatic neuroendocrine tumors (pNETs) significantly improved survival for all patients except those with the earliest-stage disease, a retrospective review of 4,700 patients ...

A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...

A group of researchers funded by Neuroendocrine Tumor Research Foundation (NETRF) has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine ...

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery].

SEATTLE -- Patients with small (<1 cm) pancreatic neuroendocrine tumors (pNETs) had a 5-year survival of 100% with surveillance, data from a large retrospective study showed. Surgery for small pNETs ...

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors—known as pNETs—that have dramatically different risks of recurrence following surgical treatment [or surgery]. The ...

Getting your care team in place, relieving digestive symptoms, and maintaining healthy lifestyle habits are all great ways to prep for treatment. Pancreatic cancer doesn’t have to be a death sentence.